The FDA Modernization Act 2.0 is a piece of legislation that updated and modernized prior regulations governing the approval and use of medical products in the United States. One of the key provisions of the act is the promotion of the use of advanced cell culture systems, including microphysiological systems (MPS), in the testing and development of new medical products.
MPS are advanced cell culture systems that closely mimic the structure and function of human tissues and organs. These systems are becoming increasingly popular in the pharmaceutical and cosmetic industries. This is due to their ability to provide more accurate and reliable information about the safety and effectiveness of new products. The ability to mimic the in vivo environment within inexpensive in vitro models means quicker development times and lower costs to develop new products.
The FDA Modernization Act 2.0 promotes the use of these systems by providing a clear regulatory framework for their use in the testing and approval of medical products. The act requires the FDA to establish new guidelines and standards for the use of microphysiological systems, and to provide training and support for companies and researchers looking to use these systems in their work.
The act also provides financial incentives for companies that use advanced cell culture systems, including microphysiological systems, in their product development work. This encourages companies to adopt these systems and to invest in the development of new and more advanced microphysiological systems.
One of the key benefits of the FDA Modernization Act 2.0 is that it reduces the need for animal testing. Traditional animal testing methods can be time-consuming, expensive, and raise ethical concerns about the treatment of animals. By promoting the use of advanced cell culture systems, including microphysiological systems, the act helps to reduce the reliance on animal testing and to promote the development of safer and more effective medical products.
The act also helps to improve the speed and efficiency of the product approval process. Traditional product testing methods can be slow and cumbersome, and they often require multiple rounds of testing to establish the safety and effectiveness of new products. By promoting the use of microphysiological systems, the FDA Modernization Act 2.0 helps to streamline the product approval process and to get new and innovative products to market more quickly.
If you are interested in learning more about our portfolio of advanced in vitro model systems, please reach out to our team to discuss your next project.
